New drug combo shows promise in early cancer trial
NCT ID NCT02159989
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 30 times
Summary
This early-phase trial tested a combination of two drugs, sapanisertib and ziv-aflibercept, in 83 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goal was to find the safest dose and identify side effects. The approach aims to slow tumor growth by blocking cell signals and cutting off the tumor's blood supply.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.